Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)
Press Release
Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer
Press Release
Electra Therapeutics to Present Clinical Data for ELA026 at the American Society of Hematology (ASH) 2023 Annual Meeting
Press Release
Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting
Press Release
Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting
Press Release
Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer
Press Release


ASH 2022 Abstract #3730

ASH 2022 Abstract #3722

ASH 2022 Abstract #2415

News Coverage

Electra Therapeutics is several years away from having a commercial product. And yet, the biotech’s new CEO Kathy Dong’s resume is stacked with experience on marketing and launching drugs—most notably, Gilead’s Sovaldi and Harvoni.
Star Therapeutics Inc. emerged from stealth mode to tell the world about its approach to drug discovery and development in rare diseases, and to spin out Electra Therapeutics Inc., the first in a projected family of companies. Deploying antibody drug discovery expertise, South San Francisco-based Star aims to generate programs that target multiple diseases with...
The first in a series of spinouts from Star targeting biology shared by multiple diseases, Electra is leveraging insights into the SIRP protein family to stop pathogenic myeloid and T cell activity via a clinical-stage lead program, with a series of preclinical assets behind it. Electra Therapeutics Inc. and its parent company Star Therapeutics both emerged...
Electra Therapeutics, a member of the Star Therapeutics constellation, is going to be reaching for some of the 7,000 rare diseases, thanks to a new $84 million series B financing. The biotech, led by ex-True North Therapeutics executives, broke cover Wednesday with a monoclonal antibody in phase 1 trials in patients with the rare inflammatory...